Mirum Pharmaceuticals, Inc. (MIRM) Earnings Call Analysis
NASDAQ · Healthcare · Biotechnology
Next earnings call: 2026-08-05
(Q2 2026)
— full calendar
Earnings Reports
-
Merum Pharmaceuticals (MIRM) Q1 2026: Rare Disease Platform Expands With $200M Global FOP Opportunity
May 07, 2026
-
MIRM Q4 2025: Net Product Sales Jump 55% as Four Registrational Readouts Approach
February 26, 2026
-
Mirim (MIRM) Q3 2025: Livmarli Drives 47% Revenue Growth as Pipeline Milestones Approach
November 05, 2025
-
MIRUM (MIRM) Q1 2025: Livmarli Tablet Approval and 61% Revenue Growth Signal Rare Disease Leadership
July 04, 2025